Case reference number US-000164 is a spontaneous case report received from a nurse and
patients mother, describing a male patient aged 7 years who experienced febrile neutropenia during treatment with 
Purixan (6-mercaptopurine). The patients relevant medical history was not reported. Concomitant 
medicationsincluded methotrexate, polyethylene glycol ( macrogol), prednisolone , ondansetron, oxycodone, 
Pentam ( pentamidine isethionate), senna ( sennoside A plus B)and Tylenol(paracetamol). On 03-Apr-2015, the 
patient started receiving Purixan (mercaptopurine) at a dose of 3.4 ml (68 mg) once daily (night) for acute 
lymphoblastic leukemia not having achieved remission. On (b) (6)  the patient was admitted to the hospital 
for 5 days due to febrile neutropenia. High fever was also reported. The cultures were negative but the patient was 
treated with intravenous cefepime and intravenous fluids for 5 days and was discharged home on (b) (6)
The treatment with Purixan was temporarily withdrawn during hospitalization due to the event and was resumed 
after 5 days at the prescribed dose. The outcome of the event febrile neutropenia was reported as recovered on(b) (6)
 The patient was discharged from hospital on (b) (6)  and had resumed the treatment with Purixan 
from an unspecified date. The reporter considered the event febrile neutropenia to be serious due to hospitalization 
Print Time: 15-JUL-2016 02:35 PM If a field is blank, there is no data for that field Page 505 of 517
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
and causality to be not related to Purixan treatment. The company considered the events to be related to Purixan. 
The submission of a report does not constitute an admission that the medical personnel, user facility, distributor, 
manufacturer or product caused or contributed to the event.